CAP Regimen in the Treatment Primary Non-small Cell Lung Cancer(NSCLC)

The paper reactted cyclophosphamide(CTX). doxorubicin(ADM). cisplatin(PDD) in the treatment primary 31 cases NSCLS. In the thirty first cases, Ⅰ of case was stage Ⅱ of the NSCLC, 10 of cases were stage Ⅲ B, 20 of cases were stage Ⅳ. Total response rate achieved 35.5%. One case achieved complete response(CR). In the thirty first cases, ten Of cases achieved partial response(PR), ten of cases were no change(NC), ten of cases were progress disease(PD).The median survival time was 8 months and in which of the response patients (CR+PR) was 17 months. The paper analysised CAP regimetn toaxicity.availability, and so.